Please find below a list of our press releases.

24 Aug 2015

Acute Pulmonary Embolism Trial (SEATTLE II) Published in the JACC: ...

EKOS Corporation, a BTG International group company (BTG plc; LSE: BTG), announced the publication of results of the SEATTLE II trial in the JACC: Cardiovascular Interventions. The study concluded that treatment with ultrasound-facilitated catheter-directed low-dose thrombolysis for acute pulmonary embolism (PE) improves right heart function, reduces blood clot size, and decreases pulmonary hypertension, in patients with intermediate to high risk PE. Importantly, no patient experienced intracranial hemorrhage, a serious adverse experience related to full-dose thrombolysis treatment.

11 Aug 2014

First Varicose Vein Patient Treated with FDA-Approved Varithena® (p...

BTG International Inc. announces that the first varicose vein patient has been treated with Varithena®

11 Jun 2014

EKOS Initiates a Pivotal New Study in Patients with Chronic Deep Ve...

EKOS Corporation, a BTG International group company (BTG plc; LSE: BTG), announces the start of patient enrollment for the ACCelerated ThrombolySiS for Post-Thrombotic Syndrome using the EKOS® System (ACCESS PTS) Study.

23 May 2014

EkoSonic® Endovascular System receives FDA Clearance for the Treatm...

EKOS Corporation, a BTG International group company announced that the U.S. Food and Drug Administration (FDA) has cleared the EkoSonic® Endovascular System for the ultrasound facilitated, controlled and selective infusion of physician-specified fluids.

30 Mar 2014

Acute Pulmonary Embolism Trial Confirms Safety and Efficacy of Ultr...

EKOS Corporation, a BTG International group company (BTG plc (LSE: BTG)), notes the presentation of the results of the SEATTLE II trial this afternoon at ACC.14, the 63rd Annual Scientific Session and Exposition of the American College of Cardiology in Washington, DC in the United States.

21 Feb 2014

BTG announces Varithena™ data demonstrating continued improvement a...

Today at the 26th Annual Meeting of the American Venous Forum in New Orleans, LA, Dr. Kenneth Todd, a Principal Investigator for VANISH-2, presented one-year data from the VANISH-2 clinical trial, one of the two pivotal trials for Varithena™ (polidocanol injectable foam).

20 Jan 2014

Pulmonary Embolism Trial Comparing Endovascular Ultrasound to Stand...

EKOS Corporation, a BTG International group company today announced the publication of the results of its Ultrasound Accelerated Thrombolysis of Pulmonary Embolism (PE) trial.

26 Nov 2013

BTG plc: FDA approves Varithena™ (polidocanol injectable foam) for ...

BTG plc, today announces that the US Food and Drug Administration (FDA) has approved Varithena™ (polidocanol injectable foam) for the treatment of patients with incompetent veins and visible varicosities of the great saphenous vein (GSV) system.

25 Jul 2013

BTG Announces Positive Results from VANISH-2 Study Data Published i...

BTG, the specialist healthcare company, today announced the online publication of VANISH-2, a study in which patients with symptomatic and visible varicose veins caused by saphenofemoral junction (SFJ) incompetence were treated with polidocanol endovenous microfoam (PEM).

8 Jul 2013

BTG PLC acquisition of EKOS

On 23 May 2013, BTG plc (BTG or the Company), the specialist healthcare company, announced that it had entered into an agreement to buy EKOS Corporation (EKOS) conditional on Hart-Scott-Rodino (HSR) approval in the US.